関節リウマチの診かた、考えかた　ver.4

出版社： 中外医学社
著者：
発行日： 2020-09-20
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784498027152
電子書籍版： 2020-09-20 （4版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,820 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,820 円(税込)

購入する

商品紹介

関節リウマチのエキスパートたちがグローバルスタンダードな診療の達成を目指してまとめあげた好評書に待望の改訂4版が登場．今版では新規治療薬および最新ガイドラインの情報を中心に改訂を行いました．関節リウマチを診る機会のある全ての医師に役立つ，本領域の決定版です．

目次

  • chapter A
    関節リウマチの診断・薬物治療
    Overview　関節リウマチ治療のパラダイムシフト
    　　　　　～スフィンクスもびっくり逆ピラミッド～
    1．診断時のこころえ 
    　A．早期診断のコツ八カ条 
    　　1．Windows of opportunity～治療開始のタイミングを逃すな～ 
    　　2．海外の診断基準も参考にしよう 
    　　3．多関節炎患者の鑑別疾患に注意！ 
    　　4．リウマトイド因子・抗CCP抗体に頼りすぎないこと 
    　　5．関節エコーやMRIを活用しよう 
    　　6．2005年早期RA診断基準を理解しておくこと 
    　　7．新しい分類基準とその問題点も知っておこう 
    　　8．問題点を踏まえたうえで，2010年分類基準を使ってみよう！ 
    　B．活動性モニター（画像も含めて） 
    2．治療戦略 
    　1．治療開始前にまず病期・予後診断 
    　2．合併症 
    　3．Treating RA To Target （T2T）
    　　　　～日常診療での治療効果判定と治療目標～ 
    　4．2019年EULAR RAの治療推奨updateと2015年ACR RA
    　　治療推奨updateについて 
    　5．コントローラーとリリーバーという考え方 
    　6．最後にやっぱり個別化医療 
    3．よく使われる消炎鎮痛薬（NSAIDsおよびステロイド） 
    　A．NSAIDsの使い方＋注意事項 
    　　1．NSAIDsの副作用 
    　　2．NSAIDsとは? 
    　　3．NSAIDsの適応 
    　　4．NSAIDsの禁忌や注意事項 
    　　5．NSAIDsの使い分け 
    　　6．まとめ 
    　B．ステロイドの使い方＋注意事項 
    　　1．ステロイドの種類 
    　　2．ステロイドの副作用 
    　　3．ステロイドの投与法・減量法 
    　　4．2007年ステロイド使用に関する欧州リウマチ学会の推奨
    　　 （EULAR recommendation） 
    4．よく使われる抗リウマチ薬 
    　1．サラゾスルファピリジン 
    　2．ブシラミン 
    　3．メトトレキサート 
    　4．イグラチモド 
    　5．トファシチニブ 
    　6．バリシチニブ 
    　7．ペフィシチニブ 
    　8．ウパダシチニブ 
    　9．アプレミラスト 
    　10．インフリキシマブ 
    　11．エタネルセプト 
    　12．アダリムマブ 
    　13．トシリズマブ 
    　14．サリルマブ 
    　15．アバタセプト 
    　16．ゴリムマブ 
    　17．セルトリズマブペゴル 
    　18．セクキヌマブ 
    　19．イキセキズマブ 
    　20．ブロダルマブ 
    　21．グセルクマブ 
    　22．リサンキズマブ 
    　23．ウステキヌマブ 
    5．その他の抗リウマチ薬 
    　1．タクロリムス 
    　2．レフルノミド 
    　3．ミゾリビン 
    6．脊椎関節炎（SpA） 
    　1．SpAとは 
    　2．SpAの臨床的特徴 
    　3．SpAの臨床所見の感度と特異度 
    　4．SpAの分類基準 
    　5．SpAの診断のポイント─原因検索─ 
    　6．強直性脊椎炎（AS）について 
    　7．乾癬性関節炎（PsA）について 

    chapter B
    こんな時どうする？　困った時のDMARDs選択
    1．肝障害がある患者のRA治療 
    2．腎障害がある患者のRA治療 
    3．肺障害がある患者のRA治療 
    4．挙児希望のある患者のRA診療 
    5．授乳中の抗リウマチ薬やその他の薬剤使用について 
    6．高齢者での注意点 

    chapter C
    内科医が知っておきたい関節リウマチの手術療法・装具療法
    1．関節リウマチ治療における手術療法の位置づけ 
    2．関節リウマチにおける手術療法の基本的な考え方 
    3．リウマチ手術療法のタイミング 
    4．リウマチ下肢の手術?：股関節と膝関節 
    5．リウマチ下肢の手術?：足関節・足部の手術 
    6．リウマチ上肢の手術 
    7．リウマチ脊椎の手術 
    8．生物学的製剤時代のリウマチ手術 
    9．関節リウマチのリハビリテーションと生活指導 
    10．関節リウマチと骨粗鬆症 

    chapter D
    日常臨床に活かす関節超音波（関節エコー）（関節超音波の基礎）
    1．関節超音波検査の特徴 
    2．機器の設定 
    3．RA早期診断への応用 
    4．疾患活動性評価への応用 
    5．予後予測への応用 
    6．その他の利点 

    chapter E
    プライマリで役立つリウマチ膠原病の漢方
    1．胃部不快感・食欲不振・るい痩 
    2．便秘 
    3．感冒・上気道炎 
    4．月経不順・月経困難・不妊 
    5．冷え症・レイノー 
    6．乾燥症状 
    7．関節炎に対する漢方治療 
    8．原因のハッキリしない発熱 
    9．漢方薬の副作用 

    chapter F
    Dr.岡田の関節リウマチ診療実況中継
    1．診察 
    2．検査 
    3．治療と説明 
    4．再診 
    5．DMARDsの開始と併用療法 
    6．サラゾスルファピリジンとブシラミン 
    7．イグラチモド 
    8．リリーバー 
    9．経口ステロイド 
    10．ステロイド関節注射 
    11．メトトレキサート 
    12．薬剤の副作用と注意点の説明 
    13．生物学的製剤/JAK阻害薬 
    14．治療目標 

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

chapter A 関節リウマチの診断・薬物治療

P.51 掲載の参考文献
1) Kuijper M, et al. EULAR. 2014.
 
2) Nishimura K, et al. Meta-analysis : diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007 ; 146 : 797-808.
PubMed
3) Combe B, et al. EULAR recommendations for the management of early arthritis : report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007 ; 66 : 34-45.
PubMed
4) Shi J, et al. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013 ; 65 : 911-5.
PubMed
5) Yee A, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res published online 13 Nov, 2014.
 
6) Maksymowych WP, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014 ; 41 : 2104-13.
 
7) McQueen FM, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis. 1998 ; 57 : 350-6.
PubMed
8) Aletaha D, et al. 2010 rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 ; 69 : 1580-8.
PubMed
9) van Dongen H, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis : A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007 ; 56 : 1424-32.
PubMed
10) Arnet FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 ; 31 : 315-24.
 
11) Wiles N, et al. Estimating the incidence of rheumatoid arthritis : trying to hit a moving terget? Arthritis Rheum. 1999 ; 42 : 1339-46.
 
12) Annette HM. Validation of a prediction rule for disease out come in patients with recent-onset undifferentiated arthritis. Arthritis Rheum. 2008 ; 58 : 2241-7.
 
13) 日本リウマチ学会ホームページ http://www.ryumachi-jp.com/info/news091030.html (2009年12月にアクセス)
 
14) Nakagomi D, et al. Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/EULAR classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum. 2013 ; 65 : 890-8.
PubMed
15) Smolen JS, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003 ; 42 : 244-57.
PubMed
16) Aletaha D, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis : validation of a clinical activity score. Arthritis Res Ther. 2005 ; 7 : 796-806.
 
17) O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004 ; 350 : 2591-602.
PubMed
18) Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study) : a single-blind randomized controlled trial. Lancet. 2004 ; 364 ; 263-9.
PubMed
19) van der Bijl AE, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007 ; 56 : 2129-34.
PubMed
20) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis : 2002 Update. Arthritis Rheum. 2002 ; 46 : 328-46.
PubMed
21) Felson DT, et al ; American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 ; 38 : 727-35.
PubMed
22) van der Haijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheum. 1999 ; 26 : 743-5.
 
23) Dougados M, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring : results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 ; 73 : 1 62-8.
PubMed
24) McInnes IB, et al The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 ; 365 : 2205-19.
PubMed
P.94 掲載の参考文献
1) Ohosone Y, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997 ; 24 : 2299-303.
PubMed
2) Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study) : a single-blind randomized controlled trial. Lancet. 2004 ; 364 : 263-9.
PubMed
3) Verstappen SMM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis : aiming for remission. Computer-Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 ; 66 : 1443-9.
PubMed
4) van der Bijl AE, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007 ; 56 : 2129-34.
PubMed
5) Smolen JS, et al. Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis. 2010 ; 69 : 631-7.
PubMed
6) Pinals RS, Baum J, Bland J, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981 ; 24 : 1308-15.
 
7) Singh JA, et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2012 ; 64 : 625-39.
PubMed
8) American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum. 2008 ; 59 : 762-84.
PubMed
9) Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update. Ann Rheum Dis. 2014 ; 73 : 492-509.
PubMed
10) Christensen E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 1984 ; 4 : 430-5.
PubMed
11) Saag KG, et al ; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 ; 59 : 762-84.
PubMed
12) McInnes IB, et al. State-of-the-art : rheumatoid arthritis. An Rheum Dis. 2010 ; 69 : 1898-906.
PubMed
13) O'Dell JR, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996 ; 334 : 1287-91.
 
14) van Vollenhoven RF, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial) : 1-year results of a randomised trial. Lancet. 2009 ; 374 : 459-66.
PubMed
15) O'Dell JR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 ; 369 : 307-18.
PubMed
P.118 掲載の参考文献
1) UpToDate 17.1 NSAIDs : Mechanism of action.
 
2) Kelley's Textbook of Rheumatology. 8th ed. Philadelphia : Saunders ; 2008. p.846.
 
3) UpToDate 17.1 NSAIDs : Adverse effects on the distal small bowel and colon.
 
4) 佐野統. 非ステロイド性抗炎症薬 (NSAIDs) の使い分け. レジデントノート. 2007 ; 9 : 837-46.
 
5) 関節リウマチの診療マニュアル (改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン. 第3章. http://www.rheumanet.or.jp/rheuma/rm400/library/guideline.html (PDFはhttp://www.rheuma-net.or.jp/rheuma/rm400/library/pdf/guideline1to4.pdf)
 
6) Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998 ; 93 : 2037-46.
 
7) UpToDate 17.1 NSAIDs (including aspirin) : Primary prevention of gastroduodenal toxicity.
 
8) 日本腎臓学会, 編. CKD診療ガイド 2009. 東京 : 東京医学社 ; 2009.
 
9) Zochling J, et al. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol. 2006 ; 25 : 794-800.
PubMed
10) Poddubnyy D, et al. Ann Rheum Dis online first on Mar 29, 2012.
 
11) 西垂水和隆. 鎮痛薬・湿布薬の使い分け. レジデントノート. 2008 ; 10 : 1028-33.
Medical*Online
12) Mason L, et al. Topical NSAIDs for chronic musculoskeletal pain : systematic review and meta-analysis. BMC Musculoskelet Disord. 2004 ; 5 : 28.
PubMed
13) McGettigan P, et al. Cardiovascular risk and inhibition of cyclooxygenase : a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006 ; 296 : 1633-44.
PubMed
14) Bennett JS, et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) : a science advisory from the American Heart Association. Circulation. 2005 ; 111 : 1713-6.
PubMed
15) Solomon DH, et al. The cardiovascular system in rheumatic disease : the newest "extraarticular" manifestation? J Rheumatol. 2005 ; 32 : 1415-7.
PubMed
16) Kwok CS, et al. Meta-analysis : risk of fractures with acidsuppressing medication. Bone. 2011 ; 48 : 768-76.
PubMed
17) Herzig SJ, et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009 ; 301 : 2120-8.
PubMed
18) Mackenzie IS, et al. Antiplatelet drug interactions. J Intern Med. 2010 ; 268 : 516-29.
PubMed
19) Lanza FL, et al ; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 ; 104 : 728-38.
PubMed
20) Huscher D, et al. Dose-related pattern of glucocorticoid-induced side effects. Ann Rheum Dis. 2009 ; 68 : 1119-24.
PubMed
21) Buttgereit F, et al.Glucocorticoids in the treatment of rheumatic diseases. Arthritis Rheum. 2004 ; 50 : 3408-17.
PubMed
22) Hoes JN, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 ; 66 : 1560-7.
PubMed
23) Wolfe F, et al. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia : associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 ; 54 : 628.
PubMed
24) Saag KG, et al. Low dose long-term glucocorticoid therapy in rheumatoid arthritis : An analysis of serious adverse events. Am J Med. 1994 ; 96 : 115.
PubMed
25) Yale SH, et al. Pneumocystis carini pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996 ; 71 : 5-13.
PubMed
26) Charles F, et al. Pneumocystis pneumonia. N Engl J Med. 2004 ; 350 : 2487-98.
 
27) 免疫疾患に合併するニューモシスチス肺炎の予防基準. 厚生労働省免疫疾患の合併症と治療法に関する研究班 2004年度報告書.
 
28) Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002 ; 34 : 1098-107.
PubMed
29) 岡田正人. 薬物アレルギー. In : レジデントのためのアレルギー疾患診療マニュアル. 東京 : 医学書院 ; 2006. p.248-52.
 
30) Suzuki Y, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab, published online 13 May 2014.
 
31) Buckley L, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2017 ; 69 : 1095-110.
PubMed
P.251 掲載の参考文献
1) Smedegard G. Sulphasalazine : mechanism of action in rheumatoid arthritis. Rheumatology. 1995 ; 34 (suppl 2) : 7-15.
 
2) 薬物治療コンサルテーション 妊娠と授乳 第2版. 南江堂 ; 2014.
 
3) 日本リウマチ学会・MTX診療ガイドライン策定小委員会. 関節ウマチ治療におけるメトトレキサート診療ガイドライン 2版. 2010年9月作成.
 
4) Visser K, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis. Ann Rheum Dis. 2009 ; 68 : 1086-93.
PubMed
5) Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 ; 69 : 964-75.
PubMed
6) Seideman P. Methotrexate-the relationship between dose and clinical effect. Br J Rheumatol. 1993 ; 32 : 751-3.
PubMed
7) Wegrzyn J, et al. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004 ; 63 : 1232-4.
PubMed
8) Hoekastra M, et al. Splitting high-dose oral methotrexate improves bioavailability. J Rheum. 2006 ; 33 : 481-5.
PubMed
9) DissickA, et al. Association of periodontitis with rheumatoid arthritis : a pilot study. J Periodontol. 2010 ; 81 : 223-30.
PubMed
10) Mikuls TR, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 2012 ; 64 : 3522-30.
PubMed
11) Klareskog L et al. A new model for an etiology of rheumatoid arthritis : smoking may trigger HLA-DR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006 ; 54 : 38-46.
PubMed
12) Ortiz P, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inihibitors. J Periodontol. 2009 ; 80 : 535-40.
PubMed
13) Saevarsdottir S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors : observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011 ; 63 : 26-36.
PubMed
14) Lu B, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women : a prospective cohort study. Ann Rheum Dis. 2014 ; 73 : 1914-22.
 
15) Gremese E, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis : an approach to a personalized medicine. Arthritis Care and Research. 2013 ; 65 : 94-100.
 
16) Elliott MJ, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 ; 36 : 1681-90.
PubMed
17) Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA) : a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 ; 381 : 1541-50.
PubMed
18) Schiff M, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis : two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 ; 73 : 86-94.
PubMed
19) Smolen JS, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 ; 73 : 3-5.
PubMed
20) Schiff M, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis : two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 ; 73 : 86-94.
PubMed
21) Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA) : a randomised, double-blind, controlled phase 4 trial. Lancet. 2013 ; 381 : 1541-50.
PubMed
22) Combe B, et al ; Etanercept European Investigators Network (Etanercept Study 309 Investigators). Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine : a double-blind comparison. Ann Rheum Dis. 2006 ; 65 : 1357-62.
PubMed
23) Strangfeld A, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009 ; 68 : 1856-62.
PubMed
24) Kaeley GS, et al. Impact of methotrexate dose reduction upon initiation of Adalimumab on clinical and ultrasonographic parameters in patients with moderate to severe rheumatoid arthritis. Arthritis Rheum 2013 ; 65 suppl : S1147.
 
25) Dougados M, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 ; 72 : 43-50.
 
26) Dougados M, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis : the ACT-RAY study. Ann Rheum Dis. 2014 ; 73 : 803-9.
PubMed
27) Nash P, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis : results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013 ; 65 : 718-28.
PubMed
28) Emery P, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis : results from the phase 3b, multicenter, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 ; 74 : 19-26.
 
29) Naniwa T, et al. Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int. 2009 ; 29 : 1287-91.
PubMed
30) Horikoshi M, et al. Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab. Mod Rheumatol. 2009 ; 19 : 229-34.
PubMed
31) Nakashima Y, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics : tocilizumab in combination with methotrexate. Mod Rheumatol. 2010 ; 20 : 343-52.
PubMed
32) Smolen JS, et al ; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study) : a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 ; 374 : 210-21.
 
33) Furst DE, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incom plete response to etanercept : the opposite study. Ann Rheum Dis. 2007 ; 66 : 893-9.
 
34) Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 ; 67 : 1516-23.
PubMed
35) Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 ; 353 : 1114-23.
PubMed
36) Cohen SB, et al ; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006 ; 54 : 2793-806.
PubMed
37) Yoshida K, et al. Biologic discontinuation studies : a systematic review of methods. Ann Rheum Dis. 2014 ; 73 : 595-9.
PubMed
38) Nishimoto N, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014 ; 24 : 17-25.
PubMed
39) Emery P, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014 ; 371 : 1781-92.
PubMed
40) Tanaka Y, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis : 1-year outcome of the HONOR study. Ann Rheum Dis. 2015 ; 74 : 389-95.
PubMed
41) Emery P, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis : results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 ; 74 : 19-26.
 
42) Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 ; 295 : 2275-85.
PubMed
43) Takeuchi T, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008 ; 67 : 189-94.
PubMed
44) Dixon WG, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis : lessons from interpreting data from observational studies. Arthritis Rheum. 2007 ; 56 : 2896-904.
PubMed
45) Nishimoto N, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy,in patients with rheumatoid arthritis (the STREAM study) : evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009 ; 68 : 1580-4.
 
46) Gottenberg JE, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010 ; 62 : 2625-32.
PubMed
47) Harigai M, et al. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007 ; 357 : 1874-6.
PubMed
48) Askling J, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005 ; 52 : 1986-92.
PubMed
49) Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 ; 345 : 1098-104.
PubMed
50) Gomez-Reino JJ, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk : a multicenter active-surveillance report. Arthritis Rheum. 2003 ; 48 : 2122-7.
 
51) Strangfeld A, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009 ; 301 : 737-44.
 
52) Brown SL, et al. Tumor necrosis factor antagonist therapy and lymphoma development : twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 ; 46 : 3151-8.
 
53) Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005 ; 64 : 699-703.
 
54) Wolfe F, et al. Biologic treatment of rheumatoid arthritis and the risk of malignancy : analyses from a large US observa tional study. Arthritis Rheum. 2007 ; 56 : 2886-95.
 
55) Askling J, et al. Haematopoietic malignancies in rheumatoid arthritis : lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005 ; 64 : 1414-20.
PubMed
56) Mariette X, et al. Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies : a systematic review and meta-analysis. Ann Rheum Dis 2011 ; 70 : 1895-904.
PubMed
57) Baecklund E, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006 ; 54 : 692-701.
 
58) Mariette X, et al ; Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate : a 3-year prospective study in France. Blood. 2002 ; 99 : 3909-15.
PubMed
59) Silman AJ, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine : a 20 year follow up study. Ann Rheum Dis. 1988 ; 6 : 988-92.
 
60) Balandraud N, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis : accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003 ; 48 : 1223-8.
PubMed
61) Salloum E, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996 ; 14 : 1943-9.
PubMed
62) Ekstrom K, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003 ; 48 : 963-70.
PubMed
63) Takeuchi T, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008 ; 18 : 447-54.
 
64) Dirven L, et al. Seven year results of DAS steered treatment in the BeSt study : clinical and radiological outcomes. Arthritis Rheum. 2010 ; 62 Suppl : S139.
 
65) Tanaka Y, et al ; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010 ; 69 : 1286-91.
 
66) Singh JA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis : a Cochrane overview. CMAJ. 2009 ; 181 : 787-96.
PubMed
67) Emery P, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET) : a randomised, double-blind, parallel treatment trial. Lancet. 2008 ; 372 : 375-82.
 
68) Emery P, et al. EULAR 2010 Abstract #LB0001.
 
69) Murashima A, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis : drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis. 2009 ; 68 : 1793-4.
 
70) Smolen JS, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet. 2013 ; 381 : 918-29.
 
71) Emery P, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014 ; 371 : 1781-92.
PubMed
72) Van der Heijde D, et al. ACR 2008 Abstract #995.
 
73) Brummester GR. EULAR 2010 Abstract #THU0184.
 
74) Burmester GR, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab : the randomised CONCERTO trial. Ann Rheum Dis published Online First 18 February 2014.
 
75) Nishimoto N, et al. EULAR 2010 Abstract #OP0134.
 
76) Nishimoto N, et al. EULAR 2010 Abstract #SAT0150.
 
77) Kremer JM, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial. Ann Intern Med. 2006 ; 144 : 865-76.
PubMed
78) Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005 ; 353 : 1114-23.
PubMed
79) Westhovens R, et al. Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis treated with abatacept plus methotrexate : results from the AGREE trial. Arthritis Rheum. 2009 ; 60 S10 : 638.
 
80) Schiff M, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST : a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008 ; 67 : 1096-103.
 
81) Tanaka Y, et al. APLAR 2010 Abstract #FP6-1.
 
82) Weinblatt M, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs : A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006 ; 54 : 2807-16.
PubMed
83) Schiff M, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept : the ARRIVE trial. Ann Rheum Dis. 2009 ; 68 : 1708-14.
PubMed
84) Singh JA, et al. Adverse effects of biologics : a network meta-analysis and Cochrane overview (Review). Cochrane Database Syst Rev. 2011 ; (2).
PubMed
85) Yamamoto K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 ; 10 ; 63 (10 Suppl.) : S474-S475.
 
86) Yamamoto K, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis. Arthritis Rheum. 2011 ; 10 ; 63 (10 Suppl.) : S476.
 
87) Weinblatt. et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis : results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012 : doi : 10.1093/rheumatology/kes150
 
88) Furst DE, et al. Evaluation of Two Dosing Regimens of Certolizumab Pegol for Maintenance of Clinical Response in Patients with Active Rheumatoid Arthritis : Primary Results from Doseflex, a Phase IIIB Study. Ann Rheum Dis. 2012 ; 71 (Suppl. 3) : 513.
 
89) http://clinicaltrials.gov/ct2/show/NCT01451203?term=Certolizumab+pegol+Early+RA&rank=1
 
90) Wakefield, et al. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFa PEGylated Fab# monoclonal antibody. Toxicological Sciences. 2011 ; 122 : 170-6.
PubMed
91) Mahadevan, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 ; 11 : 286-92.
PubMed
92) Clowse M, et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol. Arthritis Rheum. 2012 ; 1001 ; 64 (Suppl. 10) : S702.
 
P.272 掲載の参考文献
1) Kawai S, et al. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006 ; 33 : 2153-61.
 
2) Kremer JM, et al ; Tacrolimus-Methotrexate Rheumatoid Arthritis Study Group. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate : a six-month, open-label study. Arthritis Rheum. 2003 ; 48 : 2763-8.
 
3) Osiri M, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003 ; 1 : CD002047.
PubMed
4) Chokkalingam S, et al. Leflunomide use in the first 33 months after FDA approval : Experience in a national cohort of 3325 patients. Arthritis Rheum. 2002 ; 46 : S538.
 
P.336 掲載の参考文献
1) Eshed I, et al. MRI of enthesitis of the appendicular skeleton in spondyloarthritis. Ann Rheum Dis. 2007 ; 66 : 1553-9.
PubMed
2) van Praet L, et al. Microscopic gut inflammation in axial spondyloarthritis : a multiparametric predictive model. Ann Rheum Dis. 2013 ; 72 : 414-7.
PubMed
3) 大阪大学医学部免疫アレルギー内科ホームページ. http://www.med.osaka-u.ac.jp/pub/imed3/lab 2/page4/as.html
 
4) ASDAS (Ankylosing Spondylitis Disease Activity Score) calculatorのサイト http://www.asas-group.org/research/asdas_calculator/asdas.html
 
5) Ramiro S, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis : 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis online on May 7, 2014.
 
6) Wanders A, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis : a randomized clinical trial. Arthritis Rheum. 2005 ; 52 : 1756-65.
PubMed
7) Braun J, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis : a multicentre randomised controlled trial. Ann Rheum Dis. 2006 ; 65 : 1147-53.
PubMed
8) Clegg DO, et al. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies : a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 ; 42 : 2325-9.
PubMed
9) Chen J, et al. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2004 ; (3) : CD004524.
 
10) Haibel H, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis : a 16-week open-label trial. Ann Rheum Dis. 2007 ; 66 : 419-21.
PubMed
11) Braun J, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis : clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996 ; 23 : 659-64.
PubMed
12) Rudwaleit M, et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther. 2010 ; 12 : R43.
PubMed
13) Braun J, et al. Treatment of active ankylosing spondylitis with infliximab : a randomised controlled multicentre trial. Lancet. 2002 ; 359 : 1187-93.
PubMed
14) Van der Heijde D, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 ; 70 : 905-8.
PubMed
15) Rudwaleit M, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004 ; 63 : 665-70.
 
16) Sieper J, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis : results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis Published Online First 7 July 2012.
 
17) Braun J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 ; 52 : 2447-51.
PubMed
18) Sieper J, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010 ; 69 : 226-9.
PubMed
19) The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis : Results from a longitudinal, observational, multicenter study. Arthritis Care & Research. 2008 ; 59 : 234-40.
 
20) Plasencia C, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyoloarthritis with infliximab. Ann Rheum Dis published online May 6, 2012.
 
21) Sieper J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis : results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 ; 73 : 101-7.
PubMed
22) Sieper J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis : results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014 ; 73 : 108-13.
PubMed
23) Baraliakos X, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014 ; 73 : 710-5.
 
24) Moll JMH, Wright V. Psoriatic arthritis. Sem Arthritis Rheum. 1973 ; 3 : 51.
 
25) Gelfand JM, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005 ; 53 : 573.
PubMed
26) Wilson FC, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis : a population-based study. Arthritis Rheum. 2009 ; 61 : 233-9.
PubMed
27) Soltani-Arabshahi R, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010 ; 146 : 721-6.
PubMed
28) Wu S, et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheum. 2014 ; 66 : 304-10.
 
29) Love TJ, et al. Obesity and the risk of psoriatic arthritis : a population-based study. Ann Rheum Dis. 2012 ; 71 : 1273-7.
PubMed
30) Mumtaz A, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011 ; 70 : 272-7.
PubMed
31) Helliwell PS, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013 ; 72 : 986-91.
PubMed
32) Antoni C, et al ; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis : results of the IMPACT 2 trial. Ann Rheum Dis. 2005 ; 64 : 1150-7.
PubMed
33) Gladman DD, et al. Adalimumab for long-term treatment of psoriatic arthritis : forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007 ; 56 : 476-88.
PubMed
34) Gratacos J, et al. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis. 2007 ; 66 : 493-7.
PubMed
35) Griffiths CEM, et al. Comparison of Ustekinumab and Etanercept for moderate to severe psoriasis. N Engl J Med. 2010 ; 362 : 118-28.
PubMed
36) McInnes IB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis : 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 ; 382 : 780-9.
PubMed
37) Mc Innes IB, et al. Ustekinumab is effective in inhibiting radiographic progression in patients with active psoriatic arthritis : Integrated data analysis of two phase 3, randomized placebo-controlled studies. Ann Rheum Dis online Feb 19, 2014.
 
38) Ritchlin C, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiologic and biologic antitumor-necrosis-factor therapy : 6-month and 1 year results of the phase 3, multicenter, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 ; 73 : 990-9.
 
39) Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis : results of two phase three trials. N Engl J Med. 2014 ; 371 : 326-38.
 
40) Coates LC, et al. Results of a randomised controlled trial comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care : Tight Control Improves Outcome. Arthritis Rheum. 2013 ; 65 (suppl) : S346.
 
41) Abuabara K, et al. Cause-specific mortality in patients with severe psoriasis : a population-based cohort study in the U. K. Brit J Dermatol. 2010 ; 163 : 586-92.
 

chapter B こんな時どうする ? 困った時のDMARDs選択

P.374 掲載の参考文献
1) Calabrese LH, et al. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases : assessment and preventive strategies. Ann Rheum Dis. 2006 ; 65 : 983-9.
PubMed
2) 坪内博仁, 他. 免疫抑制・化学療法により発症するB型肝炎対策. 肝臓. 2009 ; 50 : 38-42.
 
3) Vassilopoulos D, et al. Keep a hepatitis C infection from hindering RA treatment. the Rheumatologist. 2008 ; 2 : 1-18.
 
4) 関節リウマチ治療におけるメトトレキサート治療診療ガイドライン (日本リウマチ学会). 2010年9月21日. http://www.ryumachi-jp.com/info/guideline_MTX.pdf
 
5) Salliot C, et al. Long term safety of methotrexate monotherapy in patients with rheumatoid arthritis : a systematic literature research. Ann Rheum Dis. 2009 ; 68 : 1100-4.
PubMed
6) Visser K, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis : integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009 ; 68 : 1086-93.
PubMed
7) Parke FA, et al. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004 ; 51 : 800-4.
PubMed
8) Zein NN, et al. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection : a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005 ; 42 : 315-22.
PubMed
9) Mederacke I, et al. Successful clearance of hepatitis C virus with pegylated interferonα-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis. 2010 Dec 3. [Epub ahead of print]
 
10) Niewold TB, et al. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum. 2006 ; 54 : 2335-7.
PubMed
11) Behnam SE, et al. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2010 ; 35 : 397-8.
PubMed
12) Sumida K, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res. 2013 ; 65 : 471-5.
PubMed
13) Mori S, et al. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency : a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis Published Online First 5 January 2015.
 
14) Marianne W, et al. Fertility in women with chronic inflammatory arthritides. Rheumatology. 2011 ; 50 : 1162-7.
 
15) De Man YA. Disease activity and prednisone use influences birth weight in rheumatoid arthritis pregnancies. Arthritis Rheum. 2006 ; 54 (9 Suppl) : 1319.
 
16) de Man, YA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight : results of a national prospective study. Arthritis Rheum. 2009 ; 60.11 : 3196-206.
PubMed
17) Barrett JH, et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999 ; 42 : 1219-27.
PubMed
18) de Man YA, et al. Disease activity of rheumatoid arthritis during pregnancy : Results from a nationwide prospective study. Arthritis Rheum. 2008 ; 59 : 1241-8.
PubMed
19) De Man YA, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis. 2010 ; 69 : 420-3.
 
20) Bonnie BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol. 2014 ; 26.3 : 334-40.
 
21) Lessan-Pezeshki M. Pregnancy after renal transplantation : points to consider. Nephrol Dial Transplant. 2002 ; 17 : 703-7.
PubMed
22) Kainz A, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000 ; 13 Suppl 1 : S299-300.
 
23) Costedoat-Chaulumeau N, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases : a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003 ; 48 : 3207-11.
 
24) Tacrolimus. In : Briggs GG, et al. Drugs in pregnancy and lactation 9th ed. Philadelphia : Lippincott Williams and Wilkins ; 2011. p.1381-5 (III).
 
25) 産婦人科診療ガイドライン産科編 2017 (2017年4月出版).
 
26) Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003 ; 21 : 3365-9.
PubMed
27) Berthelot JM, et al. Exposition to anti-TNF drugs during pregnancy : outcome of 15 cases and review of the literature. Joint Bone Spine. 2009 ; 76 : 28-34.
PubMed
28) Ostensen M. Therapy : are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol. 2009 ; 5 : 184-5.
PubMed
29) Katz JA, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004 ; 99 : 2385-92.
PubMed
30) Roux CH, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor TNF-α therapy. Rheumatology. 2006 ; 46 : 695-8.
 
31) Hyrich K, et al. Pregnancy outcome in women who were exposed to anti-TNF agents : results from a national population register. Arthritis Rheum. 2006 ; 54 : 2701-2.
 
32) Ventura SJ, et al. Trends in pregnancies and pregnancy rates by outcome : estimates for the United States, 1976-96. Vital Health Stat. 2000 ; 56 : 1-47.
PubMed
33) Chambers CD, et al. Pregnancy outcome following early gestational exposure to leflunomide : the Otis rheumatoid arthritis in pregnancy study. Pharmacoepidemiol Drug Saf. 2004 ; 13 : S1-334.
 
34) Chambers CD, et al. Pregnancy outcome in women exposed to adalimumab : the OTis Autoimmune Diseases in Pregnancy Project. Arthritis Rheum. 2006 ; 54 : 251-7.
 
35) Carter JD, et al. A safety assessment of TNF Antagonists during pregnancy : a review of the Food and Drug Administration database. J Rheumatol. 2009 ; 36 : 635-41.
PubMed
36) Mahadevan U, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 ; 21 : 733-8.
PubMed
37) Chambers CD, et al. Pregnancy outcome in women exposed to anti-TNF-α medications : the OTIS Rheumatoid Arthritis in Pregnancy Study. Arthritis Rheum. 2004 ; 50 : s479-80.
 
38) Ostensen M, et al. Management of RA medication in pregnant patients. Nat Rev Rheumatol. 2009 ; 5 : 382-90.
PubMed
39) Weber-Schoendorfer C, et al. Pregnancy outcome after rheumatologic MTX treatment prior to or during early pregnancy : a prospective multicenter cohort study. Arthritis Rheum 2014 ; 66 : 1101-10.
 
40) 伊藤真也, 村島温子. 父親への薬剤使用における胎児への影響 (第一章総論), 薬物治療コンサルテーション妊娠と授乳. 第2版. 南山堂 ; 2014.
 
41) Villiger PM, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis. 2010 ; 69 : 1842-4.
PubMed
42) Micu MC, et al. TNF-α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology. 2014 ; 53 : 1250-5.
 
43) Ostensen M, et al. Therapy insight : the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol. 2007 ; 3 : 400-6.
PubMed
44) Spencer JP, et al. Medications in the breast-feeding mother. Am Fam Physician. 2001 ; 64 : 119-26.
PubMed
45) 米国リウマチ学会Drug Safety Quarterly, Sep 2010. Access at http://www.rheumatology.org/publications/dsq/dsq_2010_03.pdf
 
46) Drug safety and Lactation, (ACR) Drug Safety quarterly, Vol.5 (2) Summer 2014.
 
47) James O'Dell. The Rheumatologist, July, 2012号.
 

chapter C 内科医が知っておきたい関節リウマチの手術療法・装具療法

P.432 掲載の参考文献
1) Momohara S, et al. Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis : data from a large observational cohort. J Rheumatol. 2014 ; 41 : 862-6.
PubMed
2) Matsumoto T, et al. Trends in treatment, outcomes, and incidence of orthopedic surgery in patients with rheumatoid arthritis : an observational cohort study using the Japanese national database of rheumatic diseases. J Rheumatol. 2017 ; 44 : 1575-82.
PubMed
3) 日本リウマチ学会, 編. 関節リウマチ診療ガイドライン 2014. 大阪 : メディカルレビュー社 ; 2014. p.75-87.
 
4) 仲村一郎, 他. 人工股関節全置換術の術後脱臼～予後に基づいた分類と治療指針の提案～. 整形・災害外科. 2007 ; 50 : 1031-7.
 
5) Dixon WG, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 ; 54 : 2368-76.
PubMed
6) den Broeder AA, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor : a large retrospective study. J Rheumatol. 2007 ; 34 : 689-95.
PubMed
7) Giles JT, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006 ; 55 : 333-7.
PubMed
8) Nakamura I, et al. Blockade of interleukin-6 signaling induces marked neutropenia in rheumatoid arthritis patients. J Rheumatology. 2009 ; 36 : 459.
 
9) 仲村一郎, 他. 抗IL-6受容体抗体製剤トシリズマブ投与による関節リウマチ患者の白血球数の変化. 内科. 2011 ; 108 : 739-42.
 
10) 仲村一郎, 西野仁樹. 周術期あるいは術後晩期感染症早期発見のための新しい方法論. 分子リウマチ治療. 2014 ; 7 : 93-8.
Medical*Online
11) Nakamura I, et al. Synovial impingement after posterior cruciate retaining total knee arthroplasty in rheumatoid arthritis. J Orthop Sci. 2006 ; 11 : 303-7.
PubMed
12) Fleming A, et al. Early rheumatoid disease. I. Onset. Ann Rheum Dis. 1976 ; 35 : 357-60.
PubMed
13) Michelson J, et al. Foot and ankle problems in rheumatoid arthritis. Foot Ankle Int. 1994 ; 15 : 608-13.
PubMed
14) Matsumoto T, et al. Radiologic patterning of joint damage to the foot in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 ; 66 : 499-507.
 
15) van Heiningen J, et al. The mid-term outcome of total ankle arthroplasty and ankle fusion in rheumatoid arthritis : a systematic review. BMC Musculoskelet Disord. 2013 ; 14 : 306.
PubMed
16) Hanyu T, et al. Arthroplasty for rheumatoid forefoot deformities by a shortening oblique osteotomy. Clin Orthop Relat Res. 1997 ; 338 : 131-8.
PubMed
17) 仲村一郎, 滝澤祐子. 関節リウマチ. In : 伊藤利之, 赤居正美, 編日本整形外科学会・日本リハビリテーション医学会, 監修. 義肢装具のチェックポイント. 東京 : 医学書院 ; 2014. p.306-12.
 
18) 小泉泰彦, 他. リウマチ肘に対する近位棚形成術の成績. 整形外科. 2013 ; 64 : 407-12.
 
19) Matsumoto T, et al. Distal interphalangeal joint arthrodesis with the reverse fix nail. J Hand Surg Am. 2013 ; 38 : 1301-6.
 
20) Seki E, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol. 2009 ; 28 : 453-60.
PubMed
21) Lamb SE, et al. Exercises to improve function of the rheumatoid hand (SARAH) : a randomised controlled trial. Lancet. 2015 ; 385 : 421-9.
 
22) Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003 ; 423 : 349-55.
PubMed
23) 骨粗鬆症の予防と治療ガイドライン作成委員会, 編. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015.
 
24) Suzuki Y, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab. 2014 ; 32 : 337-50.
PubMed
25) Bone HG, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 ; 5 : 513-23.
PubMed
26) Leder BZ, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study) : extension of a randomised controlled trial. Lancet. 2015 ; 386 : 1147-55.
PubMed
27) 仲村一郎. 関節リウマチ患者に合併した骨粗鬆症の治療 : 抗TNF製剤は有効か? リウマチ科. 2014 ; 52 : 621-5.
 
28) Chopin F, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 ; 67 : 353-7.
 

chapter D 日常臨床に活かす関節超音波 ( 関節エコー ) ( 関節超音波の基礎 )

P.443 掲載の参考文献
1) Nakagomi D, et al. Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum. 2013 ; 65 : 890-8.
PubMed
2) Karim Z, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee : a comparison with arthroscopy and clinical examination. Arthritis Rheum. 2004 ; 50 : 387-94.
PubMed
3) Wakefield RJ, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis : a comparison with conventional radiography. Arthritis Rheum. 2000 ; 43 : 2762-70.
PubMed
4) Stone M, et al. Power Doppler ultrasound assessment of rheumatoid hand synovitis. J Rheumatol. 2001 ; 28 : 1979-82.
PubMed
5) Szkudlarek M, et al. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis : a comparison with dynamic magnetic resonance imaging. Arthritis Rheum. 2001 ; 44 : 2018-23.
PubMed
6) Naredo E, et al. Ultrasonographic assessment of inflammatory activity in rheumatoid arthritis : comparison of extended versus reduced joint evaluation. Clin Exp Rheumatol. 2005 ; 23 : 881-4.
PubMed
7) Naredo E, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2008 ; 59 : 515-22.
PubMed
8) Backhaus M, et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice : a pilot project. Arthritis Rheum. 2009 ; 61 : 1194-201.
 
9) Ikeda K, et al. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis : difference between patients treated with methotrexate and those treated with biological agents. J Rheumatol. 2013 ; 40 : 1967-76.
PubMed
10) Nguyen H, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission : a systematic review and meta-analysis. Rheumatology (Oxford). 2014 ; 53 : 2110-8.
PubMed
11) Ogasawara M, et al. Autofeedback from ultrasound images provides rapid improvement in palpation skills for identifying joint swelling in rheumatoid arthritis. J Rheumatol. 2012 ; 39 : 1207-14.
PubMed

chapter E プライマリで役立つリウマチ膠原病の漢方

P.455 掲載の参考文献
1) Aron DC, et al. Cushing's syndrome and pregnancy. Am J Obstet Gynecol. 1990 ; 162 : 244-52.
PubMed
2) Ohono S. Roles of Kampo medicine in treating rheumatic diseases. J Trad Med. 2007 ; 24 : 73-80.
 
3) Hobart A, et al. Habitual Hyperthermia. JAMA. 1932 ; 99 : 1860-2.
 
4) 五野由佳理, 他. 漢方薬による薬物性肝障害の症例検討. 日本東洋醫學雜誌. 2010 ; 61 : 828-33.
 
5) 萬谷直樹. 漢方薬と薬物性肝障害. 医学のあゆみ. 2005 ; 214 : 827-31.
Medical*Online
6) Hiramatsu, et al. Mesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine. Aliment Pharmacol Ther. 2012 ; 36 : 575-86.
PubMed

chapter F Dr. 岡田の関節リウマチ診療実況中継

P.518 掲載の参考文献
1) Nikiphorou E, et al. Initial DMARD therapy for early RA. Changing trends of monotherapy to triple therapy in earn (early rheumatoid arthritis network), an inception cohort. Ann Rheum Dis. 2010 ; 69 Suppl 3 : 150.
 
2) Hunder GG, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis : comparison in a prospective study. Ann Intern Med. 1975 ; 82 : 613-8.
 
3) Jacobs JW, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 2006 ; 54 : 1422-8.
PubMed
4) Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 Update. 2020 ; 79 : 685-99.
PubMed
5) McCarty DJ. Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis Rheum. 1972 ; 15 : 157-73.
PubMed
6) Ohosone Y, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997 ; 24 : 2299-303.
PubMed
7) Emery P, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014 ; 371 : 1781-92.
PubMed
8) Tanaka Y, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010 ; 69 : 1286-91.
PubMed
9) Berthelsen BG, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010 : keq185.
PubMed
10) Murashima A, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis : drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis. 2009 ; 68 : 1793-4.
 
11) Dorner T, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013 ; 72 : 322-8.
PubMed
12) Park W, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis : the PLANETAS study. Ann Rheum Dis. 2013 ; 72 : 1605-12.
 
13) Perez-Alvarez R, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies : analysis of 122 cases. Seminars in arthritis and rheumatism. Vol. 41. No. 2. WB Saunders ; 2011.
 
14) Smolen, J, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis : the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 ; 68 : 797-804.
PubMed
15) Nakashita T, et al. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014 ; 4 : e005615.
PubMed
16) Suda M, et al. Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis : a comparative study. Clin Rheumatol. 2018 ; 37 ; 2027-34.
PubMed

書評

最近チェックした商品履歴

Loading...